Royal Jelly
CAS 8031-67-2
Royal Jelly (CAS 8031-67-2) is a pharmaceutical compound with 0 bioactivity targets and 8 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
ROYAL JELLY is linked to DTXSID001042871 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| ROYAL JELLY | 35805 | SU | MTHSPL |
| Royal Jelly | 35805 | SU | MTHSPL |
| royal jelly | 35805 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Royal Jelly used for in pharmaceutical contexts?
Royal Jelly (CAS 8031-67-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Royal Jelly?
Royal Jelly has 8 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Dysphagia, Genital abscess, Increased viscosity of upper respiratory secretion, Nasal ulcer, Psoriatic arthropathy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Royal Jelly also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Bee Venom with EU status "permitted".
What clinical phase is Royal Jelly in?
No phase 1-4 clinical development badge is rendered for Royal Jelly because the matched compound identifier rows do not contain a max-phase value.